Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00473928 · ClinicalTrials.gov registry record · Phase 1

Safety of Intravitreal POT-4 Therapy for Patients With Neovascular Age-Related Macular Degeneration (AMD)

A Phase 1 study of Age-related Macular Degeneration, sponsored by Potentia Pharmaceuticals.

Completed
Registry status
Phase 1
Development phase
27
Enrollment target
6
Study locations

NCT00473928: Completed Phase 1 study of Age-related Macular Degeneration, sponsored by Potentia Pharmaceuticals.

NCT00473928 is a Phase 1 study of Age-related Macular Degeneration that has completed, run by Potentia Pharmaceuticals. The registered enrollment target is 27 participants, below the 1,507-participant average among 74 other Age-related Macular Degeneration trials with a reported enrollment target (98% lower). The trial reports 6 study locations across 5 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00473928, a Phase 1 study of Age-related Macular Degeneration, has completed, sponsored by Potentia Pharmaceuticals.

COMPLETED
Registry status
Phase 1
Development phase
27 participants
Enrollment target
6
Study locations

Study Summary

The objective of this study is to provide initial safety and tolerability information of intravitreal POT-4 for treatment of patients with AMD

Conditions Studied

Age-related Macular Degeneration

Interventions

  • DRUG POT-4

Study Locations (6)

Florida

  • United States, Florida - Gainesville
  • United States, Florida - Miami

Arizona

  • United States, Arizona - Tucson

California

  • United States, California - Beverly Hills

Minnesota

  • United States, Minnesota - Rochester

New Hampshire

  • United States, New Hampshire - Portsmouth

Trial Details

FieldValue
Enrollment Target 27 participants
Start Date 2007-05
Est. Completion 2010-02
Phase Phase 1
Potentia Pharmaceuticals

1 total trials

What the finished NCT00473928 record still lists

NCT00473928 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 27 participants, a relatively small participant target, below the 1,507-participant average among 74 other Age-related Macular Degeneration trials with a reported enrollment target (98% lower).

The record links to 1 condition, with Age-related Macular Degeneration appearing as the primary indexed condition, and to 1 intervention - of which POT-4 is the first listed.

NCT00473928 lists 6 locations in 5 states (Florida, Arizona, California).

Frequently Asked Questions

What is clinical trial NCT00473928 about?

NCT00473928 is a clinical study titled "Safety of Intravitreal POT-4 Therapy for Patients With Neovascular Age-Related Macular Degeneration (AMD)". The objective of this study is to provide initial safety and tolerability information of intravitreal POT-4 for treatment of patients with AMD

What is the current status of trial NCT00473928?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 27 participants. The study started on 2007-05. Estimated completion is 2010-02.

What conditions does trial NCT00473928 study?

This clinical trial studies the following conditions: Age-related Macular Degeneration.

What interventions are being tested in trial NCT00473928?

The interventions under investigation include: POT-4 (DRUG).

Who is sponsoring clinical trial NCT00473928?

This trial is sponsored by Potentia Pharmaceuticals, which has 1 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00473928 being conducted?

This trial has 6 study locations across Arizona, California, Florida, Minnesota, New Hampshire. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Age-related Macular Degeneration

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT00473928's enrollment target sits among peer trials

27 61st of 74 higher than 14 of 74 other Age-related Macular Degeneration trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Age-related Macular Degeneration trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00912041 · 27 participants · NA

    BrainGate2: Feasibility Study of an Intracortical Neural Interface System for Persons With Tetraplegia

  • NCT02847559 · 27 participants · Phase 2

    Optune Delivered Electric Field Therapy and Bevacizumab in Treating Patients With Recurrent or Progressive Grade 2 or 3 Meningioma

  • NCT03380195 · 27 participants · NA

    Effects of Watermelon Juice on Heart Rate Recovery and Post-exercise Muscle Soreness

  • NCT03384238 · 27 participants · Phase 1

    Panitumumab-IRDye800 in Patients With Pancreatic Cancer Undergoing Surgery

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Related registry views

Source: ClinicalTrials.gov NCT00473928, the US trial registry maintained by the National Library of Medicine. NCT00473928 (small enrollment · multi site footprint · completed) retrieved and formatted by PlainTrial, see methodology.